scholarly journals Phenytoin intoxication with no symptoms correlated with serum drug level: a case study

2015 ◽  
Vol 22 ◽  
Author(s):  
Mucahit Avcil ◽  
Ali Duman ◽  
Kenan Ahmet Turkdogan ◽  
Mucahit Kapci ◽  
Ayhan Akoz ◽  
...  
Keyword(s):  
Drug Level ◽  
Serum Drug Level

scholarly journals Prescribing Habits for Theophylline Preparations

1983 ◽  
Vol 76 (11) ◽  
pp. 917-919 ◽  
Author(s):  
J K Wiffen ◽  
S H D Jackson
Keyword(s):  
Slow Release ◽  
Drug Level ◽  
Prescribing Habits ◽  
Serum Drug Level ◽  
Drug Level Monitoring ◽  
Level Monitoring

Information concerning the prescriptions for theophylline preparations for a group of 80 inpatients and 55 outpatients were examined. Slow-release preparations were overwhelmingly preferred. The majority of patients were receiving low daily doses of theophylline or equivalent, and serum drug level monitoring was almost non-existent.

Predicting serum drug level using the principles of pharmacokinetics after an overdose: a case of lithium overdose

2017 ◽  
Vol 25 (4) ◽  
pp. 391-394 ◽  
Author(s):  
Irosh Fernando
Keyword(s):  
Drug Overdose ◽  
Clinical Case ◽  
Drug Level ◽  
Optimum Time ◽  
Drug Levels ◽  
Lithium Overdose ◽  
Serum Drug Level

Objective: In cases of drug overdose, clinicians often find it challenging to predict serum drug level and decide the optimum time for recommencing the overdosed drug. Method: This paper describes how to predict serum drug level using the principles of pharmacokinetics. Results: The proposed method and recommencement of the overdosed drug is demonstrated using a clinical case of lithium overdose. Conclusion: The proposed method can assist clinicians in predicting serum drug levels and deciding the optimum time for recommencing the overdosed drug safely. Therefore, it may reduce unnecessary repeat serum drug level procedures.

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation

2017 ◽  
Vol 24 (8) ◽  
pp. 599-603 ◽  
Author(s):  
Tyler K Liebenstein ◽  
Kristin M Widmer ◽  
Michael J Fallon
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fungal Infection ◽  
Invasive Fungal Infection ◽  
Myeloid Leukemia ◽  
Oral Absorption ◽  
Drug Level ◽  
Tablet Formulation ◽  
Infection Prophylaxis ◽  
Serum Drug Level ◽  
Acute Myeloid

Background Posaconazole is approved for invasive fungal infection prophylaxis in patients with hematologic malignancies. Posaconazole suspension is plagued by poor oral absorption and dietary requirements that are difficult for patients to meet. The delayed-release tablet formulation of posaconazole may be taken without regards to meals and has significantly better oral absorption than posaconazole suspension. Objectives We sought to determine if a switch to posaconazole tablets improved steady-state drug level attainment for invasive fungal infection prophylaxis in patients with acute myeloid leukemia. Methods All adult inpatients with acute myeloid leukemia undergoing chemotherapy, who received posaconazole for invasive fungal infection prophylaxis between 2012 and 2015, were included. The primary outcome was proportion of patients with first posaconazole level greater than 700 ng/mL. Secondary outcomes included proportion of patients with first posaconazole level greater than 1000 ng/mL, invasive fungal infection within 100 days, and adverse drug events. Results Forty patients received posaconazole tablets and 34 patients received suspension. Posaconazole levels were significantly higher at first measurement in patients receiving tablet than suspension (1296 ng/mL vs. 788 ng/mL, p < 0.01). Thirty-seven patients receiving tablets had a serum drug level greater than 700 ng/mL on first measurement versus 18 receiving suspension (p < 0.01). Patients receiving tablets were also more likely to have a serum drug level over 1000 ng/mL on first measurement (26 vs. 11, p < 0.01). Rates of invasive fungal infection and adverse events were not statistically different. Conclusions Patients receiving posaconazole tablets attained significantly higher serum drug levels than those receiving suspension.

scholarly journals ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS

2016 ◽  
Vol 25 (3) ◽  
pp. 127-135
Author(s):  
Claudia Deaconu ◽  
◽  
Daniela Opris ◽  
Ruxandra Ionescu ◽  
◽  
...  
Keyword(s):  
Disease Activity ◽  
Drug Level ◽  
Daily Practice ◽  
Serum Levels ◽  
Antibody Detection ◽  
Therapeutic Drug ◽  
Study Cohort ◽  
Serum Drug Level ◽  
One Year ◽  
Trough Levels

Objective. The purpose of the present study was to assess the relevance of therapeutic drug monitoring in spondyloarthritis patients, by determining drug serum levels and anti-drug antibodies and estimating cut-off values for three TNF inhibitors. Methods. Over one year, we enrolled 100 patients with SpA, under consequent treatment with adalimumab (ADL), etanercept (ETA) or infliximab (IFX). Demographic, clinical (BASDAI, ASDAS) and laboratory (ESR, CRP) data was collected together with drug serum level and anti-drug antibodies using the ELISA technique. The statistical analysis was performed using the SPSS software, version 20.0 with the aid of Student t-test, Spearman and Pearson tests. Results. Out of the study cohort, 35% were on ADL, 33% on IFX, and 32% under ETA treatment. Undetectable drug levels correlated to the presence of anti-drug antibodies and to disease activity scores. There were no identified anti-ETA antibodies. For this study lot trough levels are estimated between 2 and 4 μg/mL for an ASDAS-CRP under 2.1. Conclusion. Serum drug level measurement and anti-drug antibody detection can be used as a completion to a clinician’s tools in assessing disease activity, leading to an optimal and personalized manner of patient management.

Sign in / Sign up

Export Citation Format

Share Document